Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 44 results for heart transplantation

  1. Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (MA review of TA823) [ID6324]

    In development [GID-TA11616] Expected publication date: 23 July 2025

    Technology appraisal guidance
    In development

  2. Percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for ventricular tachycardia (IPG295)

    Evidence-based recommendations on percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for ventricular tachycardia. This involves using heat to destroy selected areas of the heart to prevent the occurrence or conduction of abnormal electrical activity.

    Interventional procedures guidance
    Published
    27 March 2009
    View recommendations

    Sections for IPG295

  3. Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation ID5073

    In development [GID-TA10959] Expected publication date: 23 July 2025

    Technology appraisal guidance
    In development

  4. Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer ID6256

    In development [GID-TA11279] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  5. Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]

    In development [GID-TA11277] Expected publication date: 13 August 2025

    Technology appraisal guidance
    In development

  6. Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]

    In development [GID-TA11232] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  7. Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]

    In development [GID-TA11140] Expected publication date: 23 July 2025

    Technology appraisal guidance
    In development

  8. Cardiac contractility modulation device implantation for heart failure (IPG655)

    Evidence-based recommendations on cardiac contractility modulation device implantation for heart failure in adults. This involves placing a device under the skin of the chest, which delivers electrical pulses to make the heart contract more strongly.

    Interventional procedures guidance
    Published
    26 June 2019
    View recommendations

    Sections for IPG655

  9. Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease (TA809)

    Evidence-based recommendations on imlifidase (Idefirix) for desensitisation treatment before kidney transplant in people with chronic kidney disease.

    Technology appraisal guidance
    Published
    20 July 2022
    View recommendations

    Sections for TA809

  10. Extracorporeal membrane oxygenation (ECMO) for acute heart failure in adults (IPG482)

    Evidence-based recommendations on extracorporeal membrane oxygenation (ECMO) for acute heart failure in adults. This involves using an artificial lung to oxygenate the blood outside the body.

    Interventional procedures guidance
    Published
    27 March 2014
    View recommendations

    Sections for IPG482

  11. Partial left ventriculectomy (the Batista procedure) (IPG41)

    Evidence-based recommendations on partial left ventriculectomy. This involves reducing the size of a part of the heart so it can pump blood more efficiently.

    Interventional procedures guidance
    Published
    25 February 2004
    View recommendations

    Sections for IPG41

  12. NICE encourages further research into normothermic extracorporeal preservation of hearts for transplantation following donation after brainstem death. Outcomes should include primary graft function, graft function in the long term and device-related complications.

    further research into normothermic extracorporeal preservation of hearts for transplantation following donation after...

    Research recommendation
    Published
    21 March 2016

  13. COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NG188)

    This guideline covers identifying, assessing and managing the long-term effects of COVID-19, often described as ‘long COVID’. It makes recommendations on care in all healthcare settings for adults, children and young people who have new or ongoing symptoms 4 weeks or more after the start of acute COVID-19. It also includes advice on organising services for long COVID.

    COVID-19 rapid guideline
    Last updated
    25 January 2024

    Sections for NG188

  14. Committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  15. Infliximab for acute exacerbations of ulcerative colitis (TA163)

    Evidence-based recommendations on infliximab (Remicade) for treating acute exacerbations of severely active ulcerative colitis in adults.

    Technology appraisal guidance
    Published
    17 December 2008
    View recommendations

    Sections for TA163